The enzyme poly(ADP-ribose)glycohydrolase (PARG) is critical for the response of cells to DNA damage, and genetic and biochemical evidence indicates that PARG inhibition is a tantalizing strategy for the treatment of cancer and possibly other disease. Unfortunately, no potent, selective, and cell permeable inhibitors of PARG exist, thus there are no suitable small molecule probes to study the cellular function of this enzyme and to examine its therapeutic potential. The lack of suitable PARG inhibitors is directly attributable to the lack of an assay that can be used to monitor PARG enzymatic activity in a high-throughput fashion; the standard PARG enzymatic assay uses radiolabeled poly(ADP-ribose) and thin-layer chromatography. We have recently developed a novel PARG substrate in which a chromophore is liberated by PARG-mediated cleavage. Using this substrate, we have now conducted pilot screens in 384-well plates using liquid handling robots and full-length human PARG, and these experiments show this assay to be robust and excellent for the identification of PARG inhibitors. We now propose (in Specific Aim 1) to use this novel assay to screen ~200,000 compounds at the University of Illinois High- Throughput Screening Facility (HTSF). As described in Specific Aim 2, we have developed a critical path for follow-up experiments based on a tiered series of increasingly stringent secondary assays, both in vitro and cell culture analyses. Our goal by the end of the two-year funding period is to have identified a potent, selective, and cell permeable PARG inhibitor that can be widely used by the community for the interrogation of PARG activity in cells and for probing the potential of PARG inhibition for the treatment of various disease.

Public Health Relevance

Poly(ADP-ribose)glycohydrolase (PARG) is an enzyme of critical importance to the DNA damage repair response, and its inhibition has significant potential in treating cancer and other diseases. There are no potent and cell permeable PARG inhibitors, and this is because the standard assay used to detect PARG activity relies on radiation and thin-layer chromatography, and is thus not suitable for high-throughput screening. We have synthesized a novel PARG substrate that generates a chromophore upon PARG-mediated hydrolysis, and we now propose to use this assay to screen a collection of ~200,000 compounds to identify PARG inhibitors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA212732-01A1
Application #
9317785
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Forry, Suzanne L
Project Start
2017-03-15
Project End
2019-02-28
Budget Start
2017-03-15
Budget End
2018-02-28
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Illinois Urbana-Champaign
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
041544081
City
Champaign
State
IL
Country
United States
Zip Code
61820
Drown, Bryon S; Shirai, Tomohiro; Rack, Johannes Gregor Matthias et al. (2018) Monitoring Poly(ADP-ribosyl)glycohydrolase Activity with a Continuous Fluorescent Substrate. Cell Chem Biol 25:1562-1570.e19
Rack, Johannes Gregor Matthias; Ariza, Antonio; Drown, Bryon S et al. (2018) (ADP-ribosyl)hydrolases: Structural Basis for Differential Substrate Recognition and Inhibition. Cell Chem Biol 25:1533-1546.e12